Q-omics provides the consensus-scored RPS24P16 profile across patient tissues and cancer cell-line models. RPS24P16 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RPS24P16 is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, RPS24P16 RNA expression shows 6,897 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight BLCA, COAD, and OV as cancer lineages where RPS24P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS24P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS24P16 survival associations across molecular data types. RPS24P16 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS24P16 RNA expression–survival associations across cancer types. High RPS24P16 expression shows unfavorable associations in BLCA, ESCA, MESO and LUSC, but favorable associations in KICH and BRCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .014). Together, the overview and detailed table identify BLCA as the clearest survival context for RPS24P16 RNA expression.
This table summarizes RPS24P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPS24P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS24P16 shows higher tumor expression in COAD, PRAD and LUAD. The COAD box plot shows higher RPS24P16 RNA expression in tumor versus normal tissue (log2 FC = +1.210, t-test p < 0.001).
This table shows molecular features associated with RPS24P16 in patient tissues and cancer cell lines. In patient samples, RPS24P16 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
